Cargando…

Hospitalization Rates and Comorbidities in Patients with Progressive Supranuclear Palsy in Germany from 2010 to 2017

Progressive supranuclear palsy (PSP) belongs to the disease spectrum of Parkinsonian syndromes. Due to the chronic and progressive neurodegenerative course of the disease, PSP patients often have to be hospitalized to undergo diagnostic and therapeutic measures. The dynamics and characteristics of P...

Descripción completa

Detalles Bibliográficos
Autores principales: Zella, Maria Angela Samis, Bartig, Dirk, Herrmann, Lennard, Respondek, Gesine, Höglinger, Günter, Gold, Ralf, Woitalla, Dirk, Krogias, Christos, Tönges, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465231/
https://www.ncbi.nlm.nih.gov/pubmed/32751888
http://dx.doi.org/10.3390/jcm9082454
_version_ 1783577542523879424
author Zella, Maria Angela Samis
Bartig, Dirk
Herrmann, Lennard
Respondek, Gesine
Höglinger, Günter
Gold, Ralf
Woitalla, Dirk
Krogias, Christos
Tönges, Lars
author_facet Zella, Maria Angela Samis
Bartig, Dirk
Herrmann, Lennard
Respondek, Gesine
Höglinger, Günter
Gold, Ralf
Woitalla, Dirk
Krogias, Christos
Tönges, Lars
author_sort Zella, Maria Angela Samis
collection PubMed
description Progressive supranuclear palsy (PSP) belongs to the disease spectrum of Parkinsonian syndromes. Due to the chronic and progressive neurodegenerative course of the disease, PSP patients often have to be hospitalized to undergo diagnostic and therapeutic measures. The dynamics and characteristics of PSP inpatient treatment in Germany have not been investigated thus far. The current study analyzed trends of inpatient treatment in Germany for the years 2010–2017 based on the German DRG statistics (“diagnostic-related groups”) in the category G23.- (other degenerative diseases of the basal ganglia) and with special focus on PSP (G23.1). Inpatient case numbers of the G23.- category comprised a total of 21,196 patients from 2010–2017, whereas the PSP subcategory (G23.1) amounted to 10,663 cases. In the analyzed time period, PSP patient numbers constantly increased from 963 in 2010 to 1780 in 2017 with yearly growth rates of up to 20%. Similar trends were observed for other Parkinsonian syndromes such as multiple system atrophy (MSA). Differentiating PSP inpatients by gender demonstrated a higher proportion of males (55–60%) in comparison to female patients for the entire observation period. The average age of hospitalized PSP patients over these years was between 72.3 and 73.4 years without relevant differences for gender. The most common comorbidities consisted of cardiovascular, neurological, muscular and urological disorders. In summary, the analysis demonstrates that PSP patients are increasingly hospitalized in Germany and the current concepts of stationary care have to differentiate standard practices for Parkinson’s disease (PD) to also address the needs of patients with PSP and other Parkinsonian syndromes.
format Online
Article
Text
id pubmed-7465231
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74652312020-09-04 Hospitalization Rates and Comorbidities in Patients with Progressive Supranuclear Palsy in Germany from 2010 to 2017 Zella, Maria Angela Samis Bartig, Dirk Herrmann, Lennard Respondek, Gesine Höglinger, Günter Gold, Ralf Woitalla, Dirk Krogias, Christos Tönges, Lars J Clin Med Article Progressive supranuclear palsy (PSP) belongs to the disease spectrum of Parkinsonian syndromes. Due to the chronic and progressive neurodegenerative course of the disease, PSP patients often have to be hospitalized to undergo diagnostic and therapeutic measures. The dynamics and characteristics of PSP inpatient treatment in Germany have not been investigated thus far. The current study analyzed trends of inpatient treatment in Germany for the years 2010–2017 based on the German DRG statistics (“diagnostic-related groups”) in the category G23.- (other degenerative diseases of the basal ganglia) and with special focus on PSP (G23.1). Inpatient case numbers of the G23.- category comprised a total of 21,196 patients from 2010–2017, whereas the PSP subcategory (G23.1) amounted to 10,663 cases. In the analyzed time period, PSP patient numbers constantly increased from 963 in 2010 to 1780 in 2017 with yearly growth rates of up to 20%. Similar trends were observed for other Parkinsonian syndromes such as multiple system atrophy (MSA). Differentiating PSP inpatients by gender demonstrated a higher proportion of males (55–60%) in comparison to female patients for the entire observation period. The average age of hospitalized PSP patients over these years was between 72.3 and 73.4 years without relevant differences for gender. The most common comorbidities consisted of cardiovascular, neurological, muscular and urological disorders. In summary, the analysis demonstrates that PSP patients are increasingly hospitalized in Germany and the current concepts of stationary care have to differentiate standard practices for Parkinson’s disease (PD) to also address the needs of patients with PSP and other Parkinsonian syndromes. MDPI 2020-07-31 /pmc/articles/PMC7465231/ /pubmed/32751888 http://dx.doi.org/10.3390/jcm9082454 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zella, Maria Angela Samis
Bartig, Dirk
Herrmann, Lennard
Respondek, Gesine
Höglinger, Günter
Gold, Ralf
Woitalla, Dirk
Krogias, Christos
Tönges, Lars
Hospitalization Rates and Comorbidities in Patients with Progressive Supranuclear Palsy in Germany from 2010 to 2017
title Hospitalization Rates and Comorbidities in Patients with Progressive Supranuclear Palsy in Germany from 2010 to 2017
title_full Hospitalization Rates and Comorbidities in Patients with Progressive Supranuclear Palsy in Germany from 2010 to 2017
title_fullStr Hospitalization Rates and Comorbidities in Patients with Progressive Supranuclear Palsy in Germany from 2010 to 2017
title_full_unstemmed Hospitalization Rates and Comorbidities in Patients with Progressive Supranuclear Palsy in Germany from 2010 to 2017
title_short Hospitalization Rates and Comorbidities in Patients with Progressive Supranuclear Palsy in Germany from 2010 to 2017
title_sort hospitalization rates and comorbidities in patients with progressive supranuclear palsy in germany from 2010 to 2017
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465231/
https://www.ncbi.nlm.nih.gov/pubmed/32751888
http://dx.doi.org/10.3390/jcm9082454
work_keys_str_mv AT zellamariaangelasamis hospitalizationratesandcomorbiditiesinpatientswithprogressivesupranuclearpalsyingermanyfrom2010to2017
AT bartigdirk hospitalizationratesandcomorbiditiesinpatientswithprogressivesupranuclearpalsyingermanyfrom2010to2017
AT herrmannlennard hospitalizationratesandcomorbiditiesinpatientswithprogressivesupranuclearpalsyingermanyfrom2010to2017
AT respondekgesine hospitalizationratesandcomorbiditiesinpatientswithprogressivesupranuclearpalsyingermanyfrom2010to2017
AT hoglingergunter hospitalizationratesandcomorbiditiesinpatientswithprogressivesupranuclearpalsyingermanyfrom2010to2017
AT goldralf hospitalizationratesandcomorbiditiesinpatientswithprogressivesupranuclearpalsyingermanyfrom2010to2017
AT woitalladirk hospitalizationratesandcomorbiditiesinpatientswithprogressivesupranuclearpalsyingermanyfrom2010to2017
AT krogiaschristos hospitalizationratesandcomorbiditiesinpatientswithprogressivesupranuclearpalsyingermanyfrom2010to2017
AT tongeslars hospitalizationratesandcomorbiditiesinpatientswithprogressivesupranuclearpalsyingermanyfrom2010to2017